McCabe W R
Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S74-83. doi: 10.1093/clinids/5.supplement_1.s74.
Population studies from three counties indicate that meningitis occurs with a frequency of approximately 10 episodes per 100,000 population annually in the United States. Estimates based on this prevalence and a population of 2.3 X 10(8) suggest that approximately 23,000 episodes of meningitis occur annually in the United States. Available studies indicate that rapid and reasonably accurate identification of the etiologic agent can be made in greater than or equal to 75% of patients with meningitis by gram-staining of the cerebrospinal fluid, counterimmunoelectrophoresis, or other antigen detection techniques. These means of rapid diagnosis theoretically leave only approximately 7,000 episodes of meningitis annually in the United States in which empiric, as opposed to specific, therapy is necessary. Age-dependent variation in etiologic agents of meningitis markedly influences selection of therapeutic regimens. The preponderance of Enterobacteriaceae and group B streptococci as causes of meningitis in neonates has resulted in utilization of a penicillin (often ampicillin) combined with an aminoglycoside for empiric therapy. Continued high morbidity and mortality, especially in neonatal meningitis caused by Enterobacteriaceae, have been felt to reflect inadequate penetration of aminoglycosides into the cerebrospinal fluid, but careful prospective randomized studies of intrathecal and intraventricular administration of aminoglycosides failed to demonstrate any enhancement of therapeutic results. Ampicillin appeared to be an ideal agent for empiric therapy in older children, in whom meningitis is usually caused by Haemophilus influenzae, with Streptococcus pneumoniae and Neisseria meningitidis being less frequently implicated as etiologic agents. The occurrence of beta-lactamase-mediated resistance to ampicillin in as high as 15% of isolates of H. influenzae has resulted in combined use of ampicillin and chloramphenicol for meningitis in children. This approach is complicated by evidence of clinically important antagonism between ampicillin and chloramphenicol. Since almost all community-acquired meningitis in otherwise healthy adults is caused by meningococci and pneumococci, penicillin remains the agent of choice. In contrast, meningitis following trauma to and surgery involving the central nervous system and in the elderly is often caused by gram-negative bacilli and other "unusual" organisms; therapeutic problems in this group parallel those observed in neonatal meningitis.
来自三个县的人口研究表明,在美国,脑膜炎的发病频率约为每年每10万人口中有10例。根据这一患病率以及2.3×10⁸的人口数量估算,美国每年约有23000例脑膜炎发病。现有研究表明,通过脑脊液革兰氏染色、对流免疫电泳或其他抗原检测技术,在≥75%的脑膜炎患者中能够快速且较为准确地鉴定出病原体。从理论上讲,这些快速诊断方法使得美国每年仅有约7000例脑膜炎病例需要进行经验性而非特异性治疗。脑膜炎病原体的年龄依赖性差异显著影响治疗方案的选择。新生儿脑膜炎的主要病因是肠杆菌科细菌和B组链球菌,这导致经验性治疗采用青霉素(通常是氨苄西林)联合氨基糖苷类药物。尤其是由肠杆菌科细菌引起的新生儿脑膜炎,其高发病率和高死亡率一直被认为是氨基糖苷类药物在脑脊液中渗透不足所致,但对氨基糖苷类药物鞘内和脑室内给药的仔细前瞻性随机研究未能证明治疗效果有任何提高。氨苄西林似乎是大龄儿童经验性治疗的理想药物,大龄儿童脑膜炎通常由流感嗜血杆菌引起,肺炎链球菌和脑膜炎奈瑟菌作为病原体的情况较少。高达15%的流感嗜血杆菌分离株对氨苄西林产生β-内酰胺酶介导的耐药性,这导致儿童脑膜炎采用氨苄西林和氯霉素联合治疗。这种方法因氨苄西林和氯霉素之间存在临床上重要的拮抗作用而变得复杂。由于几乎所有健康成年人社区获得性脑膜炎都是由脑膜炎球菌和肺炎球菌引起的,青霉素仍然是首选药物。相比之下,中枢神经系统创伤和手术后以及老年人中的脑膜炎通常由革兰氏阴性杆菌和其他“不常见”病原体引起;这组患者的治疗问题与新生儿脑膜炎中观察到的问题相似。